This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Delsol, G. Articles by Mason, D. Y. Search for Related Content PubMed PubMed Citation Articles by Delsol, G. Articles by Mason, D. Y.

American Journal of Pathology, Vol 130, 59-70, Copyright © 1988 by American Society for Investigative Pathology

REGULAR ARTICLES

Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis

G Delsol, T Al Saati, KC Gatter, J Gerdes, R Schwarting, P Caveriviere, F Rigal- Huguet, A Robert, H Stein and DY Mason
Laboratoire d' Anatomie Pathologique, CHU Purpan, Toulouse, France.

A group of 63 cases of anaplastic large cell lymphomas (variants of diffuse large cell lymphomas often diagnosed as "malignant histiocytosis") was characterized on both morphologic criteria and expression of epithelial membrane antigen (EMA) and Ki-1 antigen (CD30). On the basis of the reactivity of these tumors with anti-EMA and anti-Ki-1 antibodies, four subtypes could be distinguished. In the majority of cases (n = 49), neoplastic cells coexpressed EMA and Ki-1 antigens. Nineteen of these cases were tested for IL-2R, and all were positive (Type I, EMA+, Ki-1+, IL-2R+). In the second group (n = 5), the neoplastic cells expressed EMA but not the Ki-1 antigen. These cases were not tested for the presence of IL-2R (Type II, EMA+, Ki-1-, IL-2R?). There were tumors with similar morphology expressing only Ki-1 antigen (Type III, EMA-, Ki-1+, IL-2R-) or negative for both EMA and Ki- 1 antigens (Type IV, EMA-, Ki-1-, IL-2R-). EMA appeared to occur predominantly on activated cells, as has been previously shown for Ki-1 antigen. Analysis using monoclonal antibodies to T-cell, B-cell, or macrophage-associated differentiation antigens showed that these tumors were heterogeneous in terms of cell lineage. Tumors coexpressing EMA, Ki-1, and IL-2R (Type I), were most commonly of T-cell origin (n = 12); the remainder in this type expressed B-cell markers (n = 4), a mixed B/T phenotype (n = 2), or no clear phenotype (n = 9). By contrast, tumors of Types II, III, and IV were mainly from B-cell origin (n = 6) or showed a mixed B/T phenotype (n = 1). Despite the fact that a significant proportion of these cases were initially classified morphologically as "malignant histiocytosis," only 3 of the 63 cases were possibly of histiocytic origin. These results confirm that true malignant histiocytosis is rare and that most tumors with histologic features currently regarded as being consistent with this diagnosis are lymphocytic in origin and express activation antigens such as EMA, Ki-1 antigen, and IL-2R.

This article has been cited by other articles:

				O. Linden Remission of a Refractory, Anaplastic Large-Cell Lymphoma after Treatment with Daclizumab N. Engl. J. Med., September 30, 2004; 351(14): 1466 - 1467. [Full Text] [PDF]

				J. L. Kutok and J. C. Aster Molecular Biology of Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma J. Clin. Oncol., September 1, 2002; 20(17): 3691 - 3702. [Abstract] [Full Text] [PDF]

				R L Ten Berge, F G M Snijdewint, S von Mensdorff-Pouilly, R J J Poort-Keesom, J J Oudejans, J W R Meijer, R Willemze, J Hilgers, and C J L M Meijer MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form J. Clin. Pathol., December 1, 2001; 54(12): 933 - 939. [Abstract] [Full Text] [PDF]

				P. Brossart, A. Schneider, P. Dill, T. Schammann, F. Grunebach, S. Wirths, L. Kanz, H.-J. Buhring, and W. Brugger The Epithelial Tumor Antigen MUC1 Is Expressed in Hematological Malignancies and Is Recognized by MUC1-specific Cytotoxic T-Lymphocytes Cancer Res., September 1, 2001; 61(18): 6846 - 6850. [Abstract] [Full Text] [PDF]

				H. Stein, H.-D. Foss, H. Durkop, T. Marafioti, G. Delsol, K. Pulford, S. Pileri, and B. Falini CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features Blood, December 1, 2000; 96(12): 3681 - 3695. [Abstract] [Full Text] [PDF]

				F. Gilles, A. Goy, Y. Remache, P. Shue, and A. D. Zelenetz MUC1 dysregulation as the consequence of a t(1;14)(q21;q32) translocation in an extranodal lymphoma Blood, May 1, 2000; 95(9): 2930 - 2936. [Abstract] [Full Text] [PDF]

				R. J. Kreitman, W. H. Wilson, J. D. White, M. Stetler-Stevenson, E. S. Jaffe, S. Giardina, T. A. Waldmann, and I. Pastan Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies J. Clin. Oncol., April 1, 2000; 18(8): 1622 - 1636. [Abstract] [Full Text] [PDF]

				F. Turturro, P. Seth, and C. J. Link Jr. In Vitro Adenoviral Vector p53-mediated Transduction and Killing Correlates with Expression of Coxsackie-Adenovirus Receptor and {{alpha}}{{nu}}{beta}5 Integrin in SUDHL-1 Cells Derived from Anaplastic Large-Cell Lymphoma Clin. Cancer Res., January 1, 2000; 6(1): 185 - 192. [Abstract] [Full Text]

				P. Brossart, K. S. Heinrich, G. Stuhler, L. Behnke, V. L. Reichardt, S. Stevanovic, A. Muhm, H.-G. Rammensee, L. Kanz, and W. Brugger Identification of HLA-A2-Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies Blood, June 15, 1999; 93(12): 4309 - 4317. [Abstract] [Full Text] [PDF]

				S. P. Treon, J. A. Mollick, M. Urashima, G. Teoh, D. Chauhan, A. Ogata, N. Raje, J. H.M. Hilgers, L. Nadler, A. R. Belch, et al. Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced by Dexamethasone Blood, February 15, 1999; 93(4): 1287 - 1298. [Abstract] [Full Text] [PDF]

				L. Brugieres, M.C. L. Deley, H. Pacquement, Z. Meguerian-Bedoyan, M.J. Terrier-Lacombe, A. Robert, C. Pondarre, G. Leverger, C. Devalck, C. Rodary, et al. CD30+ Anaplastic Large-Cell Lymphoma in Children: Analysis of 82 Patients Enrolled in Two Consecutive Studies of the French Society of Pediatric Oncology Blood, November 15, 1998; 92(10): 3591 - 3598. [Abstract] [Full Text] [PDF]

				D. Benharroch, Z. Meguerian-Bedoyan, L. Lamant, C. Amin, L. Brugieres, M.-J. Terrier-Lacombe, E. Haralambieva, K. Pulford, S. Pileri, S. W. Morris, et al. ALK-Positive Lymphoma: A Single Disease With a Broad Spectrum of Morphology Blood, March 15, 1998; 91(6): 2076 - 2084. [Abstract] [Full Text] [PDF]

				C. Boshoff, S.-J. Gao, L. E. Healy, S. Matthews, A. J. Thomas, L. Coignet, R. A. Warnke, J. A. Strauchen, E. Matutes, O. W. Kamel, et al. Establishing a KSHV+ Cell Line (BCP-1) From Peripheral Blood and Characterizing Its Growth in Nod/SCID Mice Blood, March 1, 1998; 91(5): 1671 - 1679. [Abstract] [Full Text] [PDF]

				H. Tilly, P. Gaulard, E. Lepage, C. Dumontet, J. Diebold, I. Plantier, F. Berger, M. Symann, T. Petrella, P. Lederlin, et al. Primary Anaplastic Large-Cell Lymphoma in Adults: Clinical Presentation, Immunophenotype, and Outcome Blood, November 1, 1997; 90(9): 3727 - 3734. [Abstract] [Full Text] [PDF]

				G. Delsol, L. Lamant, B. Mariame, K. Pulford, N. Dastugue, P. Brousset, F. Rigal-Huguet, T. Al Saati, D. P. Cerretti, S. W. Morris, et al. A New Subtype of Large B-Cell Lymphoma Expressing the ALK Kinase and Lacking the 2; 5 Translocation Blood, March 1, 1997; 89(5): 1483 - 1490. [Abstract] [Full Text] [PDF]

				E. Cesarman, Y. Chang, P. S. Moore, J. W. Said, and D. M. Knowles Kaposi's Sarcoma-Associated Herpesvirus-Like DNA Sequences in AIDS-Related Body-Cavity-Based Lymphomas N. Engl. J. Med., May 4, 1995; 332(18): 1186 - 1191. [Abstract] [Full Text] [PDF]